R
TransCode Therapeutics (RNAZ)
$000.00 0.00% ($0.00)
- Today
- Week
- Month
- Year
- 5 Year
- YTD
getbaraka.com
About TransCode Therapeutics (RNAZ)
TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. Its lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovar... Read more
- USD0.36
- USD0.36
- USD0.32
- USD66.33
- -9.70%
- --
- 1.03M
- 11.14M
- 12M
- 0.22
- -99.00%
Stock News
yesterday
Trump Media reports narrower loss, sales gain in first quarter of Trump 2.0 era
MarketWatch
yesterday
5 industrial stocks ranked for their ability to perform in uncertain economic times
CNBC
yesterday
What TSMC's April chips sales tell us about Nvidia and the AI investment trade
CNBC
yesterday
David Steiner, FedEx board member, tapped to lead U.S. Postal Service as postmaster general
CNBC
Unlock More Stock Analysis & Reports
Access detailed stock analysis from LSEG including analyst price target estimates.
